newsfilter
← Latest News
Business Wire·

Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update

-- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected in Mid-November -- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical